pp-025.2 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Monoclonal antibody therapy (non-hormonal biologic) targeting the inflammatory pathway in sJIA. For active systemic juvenile idiopathic arthritis (sJIA) in children/adolescents. Phase III
Manufacturer #7041
This pioneering genetic-engineering–based pharmaceutical company is known for its advances in child and women’s health, supported by nearly three decades of experience in biopharmaceuticals and innovative drug development. It operates tech-driven R&D platforms with over 80 pipeline projects and more than 120 marketed products. The organization is expanding into additional high-need therapeutic areas, including endocrinology, immunology and oncology, while actively pursuing global innovation and commercial partnerships.
Manufacturer usually replies in 74 days